PYC Therapeutics Limited
ASX: PYC
Pipeline milestones supported by a strong cash runway.
(Source: TradingView) 3-Month Performance Profile of PYC on a DTF compared to S&P/ASX 200 (XJO).
The company continues to strengthen its long-term outlook through steady clinical and financial progress.cash reserves standing at $153.05 million in the end of FY25, supporting ongoing development without
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
